The assessment of nuchal translucency and serum markers for down syndrome screening with ductus venosus Doppler measurements in the first trimester

Basit Öğe Kaydı
dc.authorwosidSAYIN, N. CENK/A-5801-2018
dc.contributor.authorOzer, Ozlem
dc.contributor.authorSayin, Cenk N.
dc.contributor.authorVarol, Fusun G.
dc.date.accessioned2024-06-12T11:16:46Z
dc.date.available2024-06-12T11:16:46Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: The aim of the study was to improve nuchal translucency (NT) and serum marker Down syndrome (Tri21) screening methods by including fetal ductus venosus (DV) Doppler measurements. Material and Methods: A total of 213 pregnant women were screened consecutively by combining maternal age, fetal NT and maternal serum pregnancy associated plasma protein A (PAPP-A) and free 13-human chorionic gonadotropin (f beta-1-1CG) values at 11-14 weeks of gestation. Also, a DV Doppler analysis was performed for the contribution to the screening for Tri21 and other fetal anomalies or adverse pregnancy outcomes. Results: Twelve fetuses had DV PI measurements above the 95th percentile and two (17%) developed intrauterine growth retardation. DV P1 values negatively correlated with birth weight (p=0.013, r=0.171). Two patients had T 21 among the study group (0.9%) with abnormal biochemical screening results. In these with Tri21, the combined test risk was above the suggested limit (>1/250). PAPP-A was <0.4 MoM in 23, and f beta-HCG was >1.91 MoM in 49 patients. The rates of fake positivity were 10% for PAPP-A and 22% for f beta-EICG. The sensitivity, specificity, positive and negative predictive values of the combined test was l00%,95%, 2011/1) and 100%, respectively. Conclusion: The combined test has high sensitivity and specificity for Tri21 detection. The addition of DV Doppler ultrasound in the first trimester might have the advantage of predicting some adverse pregnancy outcomes. However, in the Turkish population, further studies with larger numbers of patients will be needed to establish the usefulness of DV for the detection of Trill or the prediction of some major cardiac anomalies.en_US
dc.identifier.doi10.5152/jtgga.2010.36
dc.identifier.endpage198en_US
dc.identifier.issn1309-0399
dc.identifier.issn1309-0380
dc.identifier.issue4en_US
dc.identifier.pmid24591935en_US
dc.identifier.scopus2-s2.0-79251567115en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage194en_US
dc.identifier.trdizinid115691en_US
dc.identifier.urihttps://doi.org/10.5152/jtgga.2010.36
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/115691
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24452
dc.identifier.volume11en_US
dc.identifier.wosWOS:000420635500005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofJournal Of The Turkish-German Gynecological Associationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTurkish Populationen_US
dc.subjectDown Syndromeen_US
dc.subjectCombined Testen_US
dc.subjectDuctus Venosusen_US
dc.titleThe assessment of nuchal translucency and serum markers for down syndrome screening with ductus venosus Doppler measurements in the first trimesteren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu